SynthesisFrontiers in neurology2025
Circulating microRNAs in various etiopathogenetic subtypes of acute ischemic stroke: a human systematic review study.
Synthesis in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Stroke remains one of the leading causes of death and disability among the adult population worldwide. In recent years, considerable efforts have been made to identify circulating microRNAs that could enhance the diagnostic potential of current neuroimaging techniques and assist in the differential diagnosis of distinct pathogenetic subtypes of ischemic stroke. This systematic review aimed to examine the differential expression of microRNAs (miRNAs) across various pathogenetic forms of ischemic stroke. Methods: Web of Science, PubMed, and Scopus were searched for studies examining the association of circulating microRNAs with various etiologic subtypes of acute ischemic stroke. Studies meeting predefined inclusion and exclusion criteria were selected for data extraction. Two authors independently extracted data from the included studies regarding study design, patient characteristics, and relative microRNA expression. Results: Twelve studies were included, involving 937 cases and 690 healthy controls. The dysregulated miRNAs (let-7b, let-7e, miR-20a, miR-125b, miR-19a, miR-30a, miR-126, etc.) may serve as non-invasive biomarkers for the diagnosis of cardioembolic stroke (CE). However, the only microRNAs associated with CE and reported in more than one study were let-7b and let-7e. The highest area under the curve (AUC) value for cases with large artery atherosclerosis (LAA) was reported for miR-16 (AUC = 0.952). During small vessel occlusion (SVO), nine circulating microRNAs were found to be differentially expressed, of which seven were downregulated and two were upregulated. Conclusion: The investigation of differential microRNA expression offers significant potential for their use as biomarkers of cerebral ischemia and its etiologic subtypes. However, further research in larger patient populations is needed to validate the diagnostic utility of the identified microRNAs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.